ArticleJournal of cancer research and clinical oncology2024

Risk of HBV reactivation in HCC patients undergoing combination therapy of PD-1 inhibitors and angiogenesis inhibitors in the antiviral era.

Rui Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.